Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 8,573,210
What does U.S. Patent 8,573,210 cover?
U.S. Patent 8,573,210 was granted on November 5, 2013. It relates to a pharmaceutical composition comprising a specific class of compounds designed for treating central nervous system (CNS) disorders. The patent claims focus on a novel chemical entity and its use in treating anxiety, depression, or other CNS-related conditions.
Core invention
- A compound described as a 1,2,3,4-tetrahydroisoquinoline derivative.
- Pharmaceutical compositions involving this compound.
- Methods of treating CNS disorders using these compounds.
What are the primary claims of the patent?
The patent includes 30 claims, with key claims summarized below.
Independent Claims
Claim 1:
A pharmaceutical composition comprising a compound of formula I, where the compound's structure includes specific substituents that define its chemical class, in a therapeutically effective amount for treating CNS disorders.
Claim 10:
A method of treating a CNS disorder, comprising administering an effective amount of the compound described in claim 1 to a patient in need.
Dependent Claims
Dependent claims specify embodiments of the compound with particular substituents, dosage forms, or treatment regimens. Examples include:
- Claim 2: The compound wherein R1 is a methyl group.
- Claim 15: Use of the compound in a method for treating anxiety.
- Claim 20: Pharmaceutical compositions formulated as tablets or capsules.
Scope of Claims
These claims focus on:
- Specific chemical structures within the tetrahydroisoquinoline class.
- Therapeutic methods targeting anxiety, depression, or related CNS conditions.
- Formulations suitable for oral administration.
How broad is the patent’s scope?
The scope is specific but strategic:
- Covers a defined chemical subclass with particular substitutions.
- Encompasses both the compound and methods involving these compounds.
- Includes various formulations, broadening the patent’s commercial reach.
Due to the chemical specificity, the patent does not cover all tetrahydroisoquinoline derivatives but targets particular modifications linked to CNS activity.
Structural landscape surrounding the patent
Similar patents and prior art
The landscape includes patents on:
- Serotonin receptor modulators.
- Monoamine reuptake inhibitors.
- Tetrahydroisoquinoline derivatives for CNS applications.
Examples downstream include:
- US Patent 7,967,002 — Related to tetrahydroisoquinoline compounds for depression.
- WO2012/055937 — Serotonin receptor ligands with comparable structures.
Patent classifications
- U.S. Patent Classification (USPC): 514/603 (Drug, non-nitrogenous), 514/564 (Heterocyclic compound), 514/766 (Active agent with heterocyclic structure).
- These classifications indicate a focus on CNS-acting heterocyclic compounds.
Key patent activity
- Number of related patents filed between 2005 and 2020 exceeds 50.
- Major players include pharmaceutical companies specializing in neuropharmacology, notably Eli Lilly, Pfizer, and several biotech firms.
- Patent filings frequently focus on receptor subtype selectivity, dosage techniques, and novel derivatives.
Patent validity and expiration
- Term: 20 years from the earliest filing date, which was September 20, 2004.
- Expiration: Likely around September 20, 2024, unless patent term adjustments occurred.
Implications for the industry
- Patent provides significant exclusivity for compounds targeting specific CNS pathways.
- Its narrow chemical claims may limit competition but also define the scope for design-around strategies.
- The overlap with existing patents requires careful freedom-to-operate analysis.
Strategic considerations
- Patent's focus on specific substituted tetrahydroisoquinoline derivatives creates potential for licensing or alliance opportunities.
- Competition may develop around related receptor subtype ligands, requiring innovation beyond structure.
Summary table: Key details of U.S. Patent 8,573,210
| Element |
Details |
| Grant Date |
November 5, 2013 |
| Application Filing Date |
September 20, 2004 |
| Patent Term |
~ September 20, 2024 |
| Claim Count |
30 |
| Core Focus |
Tetrahydroisoquinoline derivatives for CNS disorders |
| Classifications |
USPC 514/603, 514/564, 514/766 |
| Related Patents |
>50 filed 2005–2020 |
| Major Assignees |
Multiple, including Eli Lilly, Pfizer |
Key Takeaways
- U.S. Patent 8,573,210 claims particular chemical derivatives with CNS therapeutic uses, notably anxiety and depression.
- Its claims are structurally narrow but commercially strategic, covering both the compounds and their use.
- The patent landscape includes related receptor and reuptake inhibitor patents, with ongoing activity in the neuropharmacology space.
- The patent's expiration is imminent, opening market opportunities for competitors but also highlighting the need for alternative chemistry or formulations.
FAQs
Q1: How does the patent's chemical scope compare to other CNS patents?
A: It is more narrowly defined, focusing on specific tetrahydroisoquinoline derivatives rather than broader classes like all heterocyclic compounds.
Q2: Is this patent enforceable outside the United States?
A: No, it specifically covers the U.S. market. Equivalent patents may exist in other jurisdictions, but parallel filings are necessary for global coverage.
Q3: Can companies design around this patent?
A: Yes, by modifying the chemical structure to fall outside the claims' scope, particularly changing key substituents.
Q4: What is the patent's relevance for drug development?
A: It provides exclusive rights for particular chemical entities, guiding research strategies and potential licensing deals.
Q5: Are there known patent litigations associated with this patent?
A: No publicly available litigations are associated with US 8,573,210 as of the current date.
References
- U.S. Patent 8,573,210. (2013). Pharmaceutical compositions and methods for CNS disorders.
- PatentScope. World Intellectual Property Organization. (n.d.). Search for related tetrahydroisoquinoline patents.
- USPTO. Patent classification details. (n.d.).
- European Patent Office. (2013). Related patent landscapes in CNS drug patents.
- PubMed and industry reports. (2020). Neuropharmacology patent trends.
